VGI Health Technology (XNEC:VTL) Other Income (Expense) : A$ Mil (TTM As of . 20)

View and export this data going back to 2021. Start your Free Trial

What is VGI Health Technology Other Income (Expense)?

VGI Health Technology's other income expense for the VGI Health Technology's pretax income for the six months ended in . 20 was A$0.00 Mil.

VGI Health Technology Other Income (Expense) Historical Data

The historical data trend for VGI Health Technology's Other Income (Expense) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

VGI Health Technology Other Income (Expense) Chart

VGI Health Technology Annual Data

Trend

Other Income (Expense)

VGI Health Technology Semi-Annual Data

Other Income (Expense)

VGI Health Technology Other Income (Expense) Calculation

Other income expense includes minority interest. Minority interest is a significant but non-controlling ownership of less than 50% of a company's voting shares by either an investor or another company.

VGI Health Technology (XNEC:VTL) Other Income (Expense) Explanation

Minority interest is reported on the consolidated income statement as a share of profit belonging to minority shareholders.

VGI Health Technology (XNEC:VTL) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » VGI Health Technology Ltd (XNEC:VTL) » Definitions » Other Income (Expense)

Comparable Companies

Traded in Other Exchanges

N/A

Address

19 Martin Place, Level 45, Suite 03, Sydney, NSW, AUS, 2003

Website

https://www.vgiht.com

VGI Health Technology Ltd develops and commercializes evidence-based nutraceuticals and pharmaceuticals. It has two evidence-based nutraceutical products ready for commercial launch in the US as well as a therapeutic drug development program. The nE1-Heart targets maintenance of heart health - tocotrienols have a similar mode of action (inhibition of HMCG CoA biosynthesis) as statins, the Gold Standard for treatment of hyperlipidaemia; and nE1-Eliteth that reduces Delayed Onset Muscle Soreness, improves muscle recovery after exercise, exercise endurance and maintenance of peak muscle power.

VGI Health Technology (XNEC:VTL) Headlines

No Headlines